GBT Announces New Employment Inducement Grants
January 06 2022 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that on January 1, 2022, the compensation committee
of GBT’s board of directors granted 10 new employees options to
purchase an aggregate of 15,225 shares of the company’s common
stock with a per share exercise price of $29.27 and restricted
stock units for an aggregate of 41,830 shares of the company’s
common stock. These awards were made under GBT’s Amended and
Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities. Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of sickle cell disease (SCD), a lifelong, devastating
inherited blood disorder. The company has introduced
Oxbryta® (voxelotor) tablets and tablets for oral suspension,
the first FDA-approved medicine that directly inhibits sickle
hemoglobin (HbS) polymerization, the root cause of red blood cell
sickling in SCD. GBT is also advancing its pipeline program in SCD
with inclacumab, a P-selectin inhibitor in Phase 3 development to
address pain crises associated with the disease, and GBT021601
(GBT601), the company’s next generation HbS polymerization
inhibitor. In addition, GBT’s drug discovery teams are working on
new targets to develop the next wave of potential treatments for
SCD. To learn more, please visit www.gbt.com and follow
the company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024